In a move to focus on its core prescription drug business, Daiichi Sankyo has agreed to divest its consumer healthcare business, Daiichi Sankyo Healthcare Co. (DSHC), to Suntry Holdings, an Osaka Japan-based food and beverage company, for JPY 246.5 billion ($1.5 billion) through a staged stock transfer.  

DSHC is positioned in Japan’s over-the-counter pharmaceutical market while also expanding into functional skincare, oral care, and food products.  

The stock transfer will be carried out in stages. Specifically, Daiichi Sankyo will transfer 30% of the issued shares of DSHC held by the company to Suntory in June 2026, and the transfer is scheduled to be completed by June 2029. 

Daiichi Sankyo says the move will allow it to concentrate its management resources on its innovative pharmaceutical business, particularly its oncology business. 

Source: Daiichi Sankyo and Suntry Holdings